The effect of bisphosphonates on bone mineral density in metastatic prostate cancer patients who are treated with anti-androgen drugs and radiotherapy

Simple item page
dc.contributor.authorKaraköse A.
dc.contributor.authorYüksel M.B.
dc.contributor.authorAydoʇdu Ö.
dc.contributor.authorGümüş B.
dc.contributor.authorAteşçi Y.Z.
dc.contributor.authorAkan Z.
dc.date.accessioned2024-07-22T08:14:29Z
dc.date.available2024-07-22T08:14:29Z
dc.date.issued2014
dc.description.abstractObjective: To evaluate the potential effect of bisphosphonates on bone mineral density (BMD) in patients who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer.; Materials and Methods: The data of 31 patients with metastatic prostate cancer who were treated with anti-androgen drugs and radiotherapy during a 1-year period were retrospectively reviewed. Patients were divided in 2 groups, in which 17 patients in group 1 were treated with zoledronic acid (4 mg/month, intravenous) and 14 patients in group 2 who did not receive zoledronic acid. BMD was measured before the treatment and at the end of the 1st year by dual energy X-ray absorptiometry. Statistical analyses were performed with the T test.; Results: Mean age of the patients was 71.42 ± 6.7(range 59-85) years. A significant increase was noted for pelvic bone, femoral neck, and lumbar vertebrae t scores when pretreatment and 1st year measurements were compared in group 1 (p < 0.05). In group 2 a significant decrease was noted for pelvic bone and femoral neck t scores at the end of the 1st year (p < 0.05). A significant increase was noted for pelvic bone and femoral neck follow-up in BMD values at the end of the 1st year compared to initial measurements in group 1. A significant decrease was noted for lumbar vertebrae follow-up in BMD values at the end of the 1st year when compared to initial values in group 2.; Conclusion: Zoledronic acid significantly increases BMD and delays unfavorable outcomes for bones in men who are treated with anti-androgen drugs and radiotherapy for metastatic prostate cancer. Copyright © 2013 S. Karger AG, Basel.
dc.identifier.DOI-ID10.1159/000365672
dc.identifier.issn16617649
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16575
dc.language.isoEnglish
dc.publisherS. Karger AG
dc.rightsAll Open Access; Gold Open Access; Green Open Access
dc.subjectantiandrogen
dc.subjectbisphosphonic acid derivative
dc.subjectzoledronic acid
dc.subjectadult
dc.subjectaged
dc.subjectantiandrogen therapy
dc.subjectArticle
dc.subjectbone density
dc.subjectbone metastasis
dc.subjectbone mineral
dc.subjectcancer patient
dc.subjectcancer radiotherapy
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectdrug effect
dc.subjectdual energy X ray absorptiometry
dc.subjectfatigue
dc.subjectfemur neck
dc.subjectfever
dc.subjectflu like syndrome
dc.subjectfollow up
dc.subjectfracture
dc.subjecthuman
dc.subjectlumbar spine
dc.subjectmale
dc.subjectmuscle spasm
dc.subjectmyalgia
dc.subjectosteoporosis
dc.subjectparesthesia
dc.subjectpelvic girdle
dc.subjectprostate cancer
dc.subjectretrospective study
dc.subjectrisk
dc.subjecttreatment outcome
dc.subjectvertebra
dc.subjectvery elderly
dc.titleThe effect of bisphosphonates on bone mineral density in metastatic prostate cancer patients who are treated with anti-androgen drugs and radiotherapy
dc.typeArticle

Files

Collections

Scopus Koleksiyonu